Developing epigenetic reprogramming medicines to extend human healthspan.
| Title |
|---|
| Head of Manufacturing Full Time South San Francisco, California, United States · Onsite |
| Scientist, Drug Product Analytical Full Time · $130K-$170K · 1+ YOE South San Francisco, California, United States · Onsite |
| Senior Scientist, mRNA engineering Full Time · $160K-$185K · 5+ YOE South San Francisco, California, United States · Onsite |
| Scientist/Senior Scientist, PK/PD Assays Full Time · $90K-$110K · 5+ YOE South San Francisco, California, United States · Onsite |
| VP, Clinical Development Full Time South San Francisco, California, United States · Onsite |
| Computational Biologist Full Time · $130K-$170K South San Francisco, California, United States · Onsite |
| Senior/Research Associate Full Time · $75K-$100K · 2+ YOE South San Francisco, California, United States · Onsite |
| Scientist/Senior Scientist, Immunology Full Time · $130K-$180K · 2+ YOE South San Francisco, California, United States · Onsite |
| Senior Research Associate, Metabolism Full Time · $90K-$105K · 2+ YOE South San Francisco, California, United States · Onsite |
| Senior Research Associate, Single Cell Technology Full Time · $90K-$110K · 2+ YOE South San Francisco, California, United States · Onsite |
| Bioinformatics Software Engineer / Analyst Full Time · $140K-$200K South San Francisco, California, United States · Onsite |
| Scientist/Senior Scientist, Vascular Full Time · 5+ YOE South San Francisco, California, United States · Onsite |
| Activities | Epigenetic reprogrammingDrug discoverySingle-cell genomicsmRNA therapeutics developmentHigh-throughput biological screening |
| Headquarters | US |
| Industries | Biotechnology |
| Name | NewLimit |
| Employees | 50 |
| Type | Private |
| Tagline | Developing epigenetic reprogramming medicines to extend human healthspan. |
| Founded | 2,021 |
| Website | newlimit.com |
| Latest Funding Round | Series B |
| Latest Funding Year | 2,025 |
| Latest Funding Amount | 45,000,000 |
| Latest Investors | Kleiner PerkinsEli Lilly and Company |